The Adcom is over and Eteplirsen was voted down. A final decision still remains for approval. While much was discussed in the Adcom, the key arguments were over these: 1..
It was not a great end of the week for the sector. Trading has not been good and earnings were fine but not exciting. As much as the sector has.
This week seems to have started like last week. I think it was actually last Tuesday that the sector suddenly took a dive on no real news and yesterday was.
Yesterday was a great day for the sector (although volumes could have been better) but I do not know why. There did not seem to be a major catalyst but.
I need to get this out early as I have meetings all morning. I apologize if it does not read well or is poorly edited. 1. One worry that cannot.
Reaching the decision point… Today is the day we have to make decisions in SRPT position. As has been explained several times in the forum and CRG twitter private.
The generally trading in the sector seems indeterminate. Stocks that underperform one day outperform the next. One day large caps outperform and the next it is small caps. The only.
*** David Sobek is a disciplined value investor. Using models, research, and fundamental data, David devises a value for biotech stocks, buys when significantly undervalued, and sells when significantly overvalued.***.
Yesterday ended up being modestly better than it started but the sector still remains in a difficult spot. It was certainly positive to see some recovery and movements higher but.
It has been a strange sort of trading. The sector did well last week but has been underperforming for a couple days now. Ideally this is simply back testing the.
While the sector did not do great on an absolute basis yesterday, it clearly outperformed the broader market. Given the relatively underperformance in the first quarter (the biggest underperformance for.
The news is obviously the failed AGN and PFE deal, so I will focus on why the deal fell through and what it means for the companies and sector. I.
Yesterday was generally a good day for the sector but it is hard to feel particularly good about it. We certainly need more time to see if this is another.
***”Economists have forecast 9 out of the last 5 recessions. *** One contribution I make to the CRG team is my background in economics. I have a pervasive interest in.
I am very surprised with the way yesterday turned out. Shrugging off the news to turn positive was impressive even if the sector underperformed the broader market. It seems to.
We start the week with some biotech news although not the M&A that many expect. I will be interested to see how MDVN trades given its takeover speculation at the.
It looks like the sector did not fall off a cliff and perhaps has been finding some support. We still have the recurring question of whether this is real buying.
You are missing a lot of private interaction we are mostly using the private feed @CRGTrades to do so, the best way to be updated is to follow us.
We are again at a decision point in the sector where it seems we are close to making another leg lower. My base case has been that there is not.